RG1662

DRUG6 trials

Sponsors

Hoffmann-La Roche

Conditions

Down SyndromeHealthy Patient StudyHealthy VolunteerHealthy Volunteer, Down Syndrome

Phase 1

A Study of RG1662 in Individuals With Down Syndrome

CompletedNCT01436955

Hoffmann-La RocheDown Syndrome

Start: 2011-11-30End: 2013-09-30Updated: 2015-03-03

A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662

CompletedNCT01667367

Hoffmann-La RocheHealthy Volunteer, Down Syndrome

Start: 2012-08-31End: 2013-10-31Updated: 2015-09-02

A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers

CompletedNCT01684891

Hoffmann-La RocheHealthy Volunteer

Start: 2012-09-30End: 2012-10-31Updated: 2016-11-02

A Study of the Effect of RG1662 on Metformin in Healthy Volunteers

CompletedNCT02342925

Hoffmann-La RocheHealthy Volunteer

Start: 2015-02-28End: 2015-05-31Updated: 2016-11-02

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects

CompletedNCT02470832

Hoffmann-La RocheHealthy Patient Study

Start: 2015-05-31End: 2015-07-31Updated: 2016-08-26

Phase 2

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

CompletedNCT02024789

Hoffmann-La RocheDown Syndrome

Start: 2014-05-05End: 2016-05-04Updated: 2017-10-25

Related Papers

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Journal of Neurodevelopmental Disorders2022-02-0540 citations